May 02, 2012
The new facility is part of BD’s efforts to accelerate R&D innovation to develop new products and markets, achieve time-to-market advantage for its products and enhance operational efficiencies. This facility will be directly managed by BD – Singapore.
According to the engagement, BD will focus on creating innovative solutions by leveraging HCL’s capabilities and service expertise such as sustenance engineering and product – testing services delivered out of this facility. HCL will also conduct product life cycle and design verification studies to support new product development initiatives and product launches for BD in the emerging markets, such as India.
“Emerging markets play a key role in addressing the innovation challenges in the healthcare industry, and we continue investing in R&D for market-appropriate solutions,” said Scott P. Bruder M.D. Ph.D., Senior Vice President and Chief Science and Technology Officer, BD. “We value our relationship with HCL, which will help us create new capabilities in the Asia Pacific region and will offer significant support to develop effective and affordable solutions and medical innovations.”
“HCL understands that the critical path for research is not only in developing products but also in harnessing medical innovations in an efficient and effective way”, said G.H. Rao, Senior Corporate Vice President, Engineering and R&D Services, HCL Technologies. “We are proud of our engagement with BD and will continue to power new ideas and help foster innovations. This engagement is yet another testimonial of HCL’s leadership in Engineering and R&D services globally.”
Recognized by industry analysts and others for its leadership in the engineering services market, HCL’s Engineering Services practice has emerged as a leading technology services partner in the U.S. and Europe. HCL has partnered with over 200 customers working on cutting edge technologies, world class products and creating an associated solution delivery ecosystem to elevate market leadership.
For more information, please click on the link below: /engineering-services/
HCL Technologies is a leading global IT services company, working with clients in the areas that impact and redefine the core of their businesses. Since its inception into the global landscape after its IPO in 1999, HCL focuses on ‘transformational outsourcing’, underlined by innovation and value creation, and offers integrated portfolio of services including software-led IT solutions, infrastructure management, engineering and R&D services and BPO. HCL leverages its extensive global offshore infrastructure and network of offices in 26 countries to provide holistic, multi-service delivery in key industry verticals including Financial Services, Manufacturing, Consumer Services, Public Services and Healthcare. HCL takes pride in its philosophy of ‘Employee First, Customer Second’ which empowers our 82,464 transformers to create a real value for the customers. HCL Technologies, along with its subsidiaries, has reported consolidated revenues of US$ 4.0 billion (` 19,412 crores), as on 31 March 2012 (on LTMbasis). For more information, please visit www.hcltech.com
HCL is a $6.2 bn leading global technology and IT enterprise comprising two companies listed in India – HCL Technologies and HCL Infosystems. Founded in 1976, HCL is one of India’s original IT garage start-ups. A pioneer of modern computing and a transformational enterprise, HCL’s diverse range of hardware and software offerings span a wide array of focused industry verticals. The HCL team consists of 90,000 professionals of diverse nationalities, who operate from 31 countries including over 500 points of presence in India. For more on HCL, please visit www.hcl.com
Certain statements in this release are forward-looking statements, which involve a number of risks, uncertainties, assumptions and other factors that could cause actual results to differ materially from those in such forward-looking statements. All statements, other than statements of historical fact are statements that could be deemed forward looking statements, including but not limited to the statements containing the words ‘planned’, ‘expects’, ‘believes’,’ strategy’, ‘opportunity’, ‘anticipates’, ‘hopes’ or other similar words. The risks and uncertainties relating to these statements include, but are not limited to, risks and uncertainties regarding impact of pending regulatory proceedings, fluctuations in earnings, our ability to manage growth, intense competition in IT services, Business Process Outsourcing and consulting services including those factors which may affect our cost advantage, wage increases in India, customer acceptances of our services, products and fee structures, our ability to attract and retain highly skilled professionals, our ability to integrate acquired assets in a cost effective and timely manner, time and cost overruns on fixed-price, fixed-time frame contracts, client concentration, restrictions on immigration, our ability to manage our international operations, reduced demand for technology in our key focus areas, disruptions in telecommunication networks, our ability to successfully complete and integrate potential acquisitions, the success of our brand development efforts, liability for damages on our service contracts, the success of the companies /entities in which we have made strategic investments, withdrawal of governmental fiscal incentives, political instability, legal restrictions on raising capital or acquiring companies outside India, and unauthorized use of our intellectual property, other risks, uncertainties and general economic conditions affecting our industry. There can be no assurance that the forward looking statements made herein will prove to be accurate, and issuance of such forward looking statements should not be regarded as a representation by the Company, or any other person, that the objective and plans of the Company will be achieved. All forward looking statements made herein are based on information presently available to the management of the Company and the Company does not undertake to update any forward-looking statement that may be made from time to time by or on behalf of the Company.
BD is a leading global medical technology company that develops, manufactures and sells medical devices, instrument systems and reagents. The Company is dedicated to improving people’s health throughout the world. BD is focused on improving drug delivery, enhancing the quality and speed of diagnosing infectious diseases and cancers, and advancing research, discovery and production of new drugs and vaccines. BD’s capabilities are instrumental in combating many of the world’s most pressing diseases. Founded in 1897 and headquartered in Franklin Lakes, New Jersey, BD employs approximately 29,000 associates in more than 50 countries throughout the world. The Company serves healthcare institutions, life science researchers, clinical laboratories, the pharmaceutical industry and the general public. For more information, please visit.
For any queries, please contact –